Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21744522 | 0.86 | ALDH1A1 (0.59) | ALDH1A1CA12CA9MAPTNPSR1 | |
| SCHEMBL21744806 | 0.85 | ALDH1A1 (0.57) | ALDH1A1CA12CA9MAPTNPSR1 | |
| SCHEMBL14553331 | 0.84 | ALDH1A1 (0.65) | ALDH1A1CA12CA9MAPTNPSR1 | |
| SCHEMBL24370220 | 0.84 | ALDH1A1 (0.65) | ALDH1A1CA12CA9MAPTNPSR1 | |
| SCHEMBL29113043 | 0.83 | CA12 (0.58) | ALDH1A1CA12CA9MAPTNPSR1 | |
| SCHEMBL10617332 | 0.81 | ALDH1A1 (0.61) | ALDH1A1CA12CA9MAPTNPSR1 | |
| SCHEMBL10296125 | 0.81 | ALDH1A1 (0.61) | ALDH1A1CA12CA9MAPTNPSR1 | |
| SCHEMBL10296009 | 0.81 | ALDH1A1 (0.61) | ALDH1A1CA12CA9MAPTNPSR1 | |
| SCHEMBL10617346 | 0.81 | ALDH1A1 (0.61) | ALDH1A1CA12CA9MAPTNPSR1 | |
| SCHEMBL12324215 | 0.79 | ALDH1A1 (0.51) | ALDH1A1CA12CA9MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010004454-A1 | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications | BRACCO SUISSE SA (CH) | 2001-06-21 | — | — | US | disclosed |
| EP-1077729-A2 | METAL COMPLEXES DERIVATIZED WITH FOLATE FOR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059640-A2 | METAL COMPLEXES DERIVATIZED WITH FOLATE FOR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010004454-A1 | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications | FOLR1, FOLR2, SLC46A1 | ALDH1A1 1176/4885CA12 320/4885CA9 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.